<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415454</url>
  </required_header>
  <id_info>
    <org_study_id>Panc4242</org_study_id>
    <secondary_id>P01CA097012</secondary_id>
    <nct_id>NCT00415454</nct_id>
  </id_info>
  <brief_title>Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the Treatment of Non-Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this phase I study is to determine the safety of combining&#xD;
      replication-competent adenovirus-mediated suicide gene therapy with chemoradiotherapy in&#xD;
      patients with non-metastatic pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
      To determine the toxicity and maximum tolerated dose (MTD) of the Ad5-yCD/mutTKSR39rep-ADP&#xD;
      adenovirus in combination with 5-fluorocytosine (5-FC) and valganciclovir (vGCV) prodrug&#xD;
      therapy and standard chemoradiation. Fifteen to 30 subjects (5 cohorts of 3 - 6 subjects&#xD;
      each) with non-metastatic, unresectable pancreatic cancer will receive a single intratumoral&#xD;
      injection of the Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of five dose levels (1 x 10e10&#xD;
      vp, 3 x 10e10 vp, 1 x 10e11 vp, 3 x 10e11 vp, 1 x 10e12 vp) under endoscopic ultrasound&#xD;
      (EUS)-guidance. Beginning three days later, subjects will receive 3 weeks (15 days) of 5-FC&#xD;
      and vGCV prodrug therapy concomitant with a 6 week (30 day) course of capecitabine&#xD;
      chemotherapy and 54 Gy conformal radiotherapy.&#xD;
&#xD;
      The primary endpoint is toxicity at 12 weeks. Secondary endpoints are: 1) tumor&#xD;
      (radiological) response, 2) time to disease progression, 3) survival, 4) persistence of&#xD;
      Ad5-yCD/mutTKSR39rep-ADP adenoviral DNA in blood, 5) infectious Ad5-yCD/mutTKSR39rep-ADP&#xD;
      adenovirus in blood, and 6) HSV-1 TK gene expression in the pancreas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment&#xD;
  </why_stopped>
  <start_date>November 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>12 weeks post adenovirus injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>3 - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>10 - 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression in pancreas</measure>
    <time_frame>1 - 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gene therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adenovirus injection followed by 3 weeks of 5-FC + vGCV prodrug therapy and a 6 week course of capecitabine-based chemoradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Ad5-yCD/mutTKSR39rep-ADP</intervention_name>
    <description>Single injection on day 1 at one of five dose levels</description>
    <arm_group_label>Gene therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; = 18 and &lt; = 80.&#xD;
&#xD;
          -  Non-metastatic, unresectable tumors&#xD;
&#xD;
          -  No evidence of peritoneal and/or hematogenous metastasis.&#xD;
&#xD;
          -  Histologically proven (biopsy or cytology) adenocarcinoma.&#xD;
&#xD;
          -  No evidence of peritoneal and/or hematogenous metastasis.&#xD;
&#xD;
          -  No prior chemotherapy, radiotherapy or biological therapy.&#xD;
&#xD;
          -  ECOG performance status 0 - 2.&#xD;
&#xD;
          -  Subjects must have adequate baseline organ function, as assessed by the following&#xD;
             laboratory values, within 30 days before initiating the study therapy:&#xD;
&#xD;
          -  Adequate renal function with serum creatinine &lt;=1.5 mg/dL or creatinine clearance &gt;=50&#xD;
             mL/min/m2.&#xD;
&#xD;
          -  Absolute WBC &gt; 4,000/μL.&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL.&#xD;
&#xD;
          -  Platelet count &gt; 100,000/μL.&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL; SGOT and SGPT &lt; 2.5 times upper limit of normal (ULN).&#xD;
&#xD;
          -  No history of malignancy within 5 years except for non-melanomatous skin cancer or&#xD;
             carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Men and women with conceptive potential must agree to follow a medically acceptable&#xD;
             method of birth control.&#xD;
&#xD;
          -  Patients on oral warfarin anticoagulation therapy may be included in this study, but&#xD;
             must have close monitoring of their coagulation parameters as altered parameters&#xD;
             and/or bleeding have been reported in patients taking Xeloda® and such agents&#xD;
             concomitantly.&#xD;
&#xD;
          -  The subject must possess the ability to give informed consent and express a&#xD;
             willingness to meet all of the expected requirements of the protocol for the duration&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Serious non-malignant disease (e.g., congestive heart failure or uncontrolled&#xD;
             infections), which, in the opinion of the investigator would compromise study&#xD;
             objectives.&#xD;
&#xD;
          -  Major surgery within four weeks other than diagnostic procedures such as laparoscopy,&#xD;
             endoscopic ultrasound and stenting or PEG/PEJ placement.&#xD;
&#xD;
          -  Islet cell tumor, benign cyst, peri-ampullary carcinoma or any non-adenocarcinomas.&#xD;
&#xD;
          -  Acute infection. Acute infection is defined by any viral, bacterial, or fungal&#xD;
             infection that has required specific therapy within 72 hours of initiation of the&#xD;
             study therapy (defined as Day 1).&#xD;
&#xD;
          -  Active HIV disease.&#xD;
&#xD;
          -  Previous history of liver disease including hepatitis.&#xD;
&#xD;
          -  Positive serologic test for Hepatitis B or C at baseline.&#xD;
&#xD;
          -  Immunosuppressive therapy including systemic corticosteroids. Use of inhaled and&#xD;
             topical corticosteroids is permitted.&#xD;
&#xD;
          -  Serious medical or psychiatric illness or concomitant medication, which, in the&#xD;
             judgment of the investigator, might interfere with the subject's ability to respond to&#xD;
             or tolerate the treatment or complete the trial.&#xD;
&#xD;
          -  Impaired immunity or susceptibility to serious viral infections.&#xD;
&#xD;
          -  Allergy to any product used on the protocol including ciprofloxacin.&#xD;
&#xD;
          -  Clinical or laboratory evidence of pancreatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Munther Ajlouni, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2006</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Svend O. Freytag, Ph.D.</name_title>
    <organization>Henry Ford Health System</organization>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Suicide</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

